NASDAQ:QNRX

Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis

Quoin Pharmaceuticals logo
$3.56 +0.20 (+5.95%)
Closing price 04:00 PM Eastern
Extended Trading
$3.53 -0.03 (-0.79%)
As of 06:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Quoin Pharmaceuticals Stock (NASDAQ:QNRX)

Advanced

Key Stats

Today's Range
$3.35
▼
$3.56
50-Day Range
$3.36
▼
$7.06
52-Week Range
$3.25
▼
$23.50
Volume
7,033 shs
Average Volume
255,952 shs
Market Capitalization
$17.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.33
Consensus Rating
Moderate Buy

Company Overview

Quoin Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing treatments for rare and orphan diseases, with an emphasis on conditions affecting the skin.

Its lead investigational product, QRX003, is a topical therapy being developed for Netherton syndrome, a rare genetic skin disorder. The company has also described plans to explore the treatment’s potential in other skin conditions. QRX003 is investigational and has not been established as a proven treatment.

AI Generated. May Contain Errors.

Quoin Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
80th Percentile Overall Score

QNRX MarketRank™: 
3.991747637425 of 5 stars

Quoin Pharmaceuticals scored higher than 80% of companies evaluated by MarketBeat, and ranked 92nd out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Quoin Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Quoin Pharmaceuticals has a consensus price target of $17.33, representing about 398.8% upside from its current price of $3.48.

  • Amount of Analyst Coverage

    Quoin Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about Quoin Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Quoin Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Quoin Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Quoin Pharmaceuticals has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.53% of the float of Quoin Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Quoin Pharmaceuticals has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Quoin Pharmaceuticals has recently increased by 17.17%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Quoin Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Quoin Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Quoin Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Quoin Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for QNRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Quoin Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Cluster Insider Buying

    4 insiders have purchased shares of Quoin Pharmaceuticals in the last three months. Multiple insiders buying is a strong bullish signal.

  • Net Insider Buying

    Over the last three months, insiders have purchased a net $279,966.00 in company stock, which represents 1.6785% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Quoin Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $279,966.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    7.54% of the stock of Quoin Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    8.63% of the stock of Quoin Pharmaceuticals is held by institutions.

  • Read more about Quoin Pharmaceuticals' insider trading history.
Receive QNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

QNRX Stock News Headlines

Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Rating Lowered by Wall Street Zen
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
See More Headlines

QNRX Stock Analysis - Frequently Asked Questions

Quoin Pharmaceuticals' stock was trading at $14.43 on January 1st, 2026. Since then, QNRX stock has decreased by 75.9% and is now trading at $3.4750.

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) issued its quarterly earnings data on Thursday, November, 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.52) by $0.55.

Quoin Pharmaceuticals shares reverse split on Monday, July 17th 2023.The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Quoin Pharmaceuticals (QNRX) raised $0 in an initial public offering on Friday, July 29th 2016. The company issued 1,292,308 shares at $0.00 per share.

Top institutional shareholders of Quoin Pharmaceuticals include Nantahala Capital Management LLC (4.92%) and AIGH Capital Management LLC (4.92%). Insiders that own company stock include Anthony James Culverwell, Michael Myers, Denise P Carter, Dennis Langer, Sally Bridget Lawlor and Gordon Dunn.
View institutional ownership trends
.

Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Quoin Pharmaceuticals investors own include Rivian Automotive (RIVN), AMC Entertainment (AMC), NIO (NIO), Pfizer (PFE), SNDL (SNDL), Tesla (TSLA) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/05/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:QNRX
CIK
1671502
Employees
4
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$14.00
Potential Upside/Downside
+386.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($19.44)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.81 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-227.75%
Return on Assets
-149.97%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.20
Quick Ratio
7.20

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.97 per share
Price / Book
0.60

Miscellaneous

Outstanding Shares
4,800,000
Free Float
4,442,000
Market Cap
$17.09 million
Optionable
Not Optionable
Beta
1.71
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:QNRX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners